The ASH Meeting on Lymphoma Biology was established in 2014 to address an unmet need in the lymphoma community: to serve as the only U.S.-based forum specifically focused on basic and translational science relevant to lymphoma and chronic lymphocytic leukemia. The central goal of the meeting is to bring together experts from around the world to discuss the latest lymphoma fundamental science, address current challenges in the field, establish the highest priorities for investigation, and develop novel therapeutics. The 2020 program will focus specifically on the following:
- Understanding the biology of lymphoma;
- Pathogenic mechanisms in lymphoma; and
- Clinical applications of novel technologies for the diagnosis and treatment of lymphomas.
The interactive format will include didactic sessions, abstract presentations, panel discussions, and informal roundtable discussions known as "Continuing Conversations" sessions.
Through participation in this meeting, attendees will be able to:
- Assess recent efforts to define the genetic and epigenetic alterations in lymphoma pathogenesis.
- Summarize the current state of cancer immunotherapy and its applications to lymphoma.
- Analyze germinal center biology and illustrate the physiological functions of germinal center reaction.
- Articulate the role of signaling pathways and microenvironmental interactions in lymphoma biology.
- Illustrate the biology of the main subtypes of germinal center B-cell derived lymphomas.
- Explain mechanisms of sensitivity and resistance to novel lymphoma therapies.
- Describe recent novel findings in chronic lymphocytic leukemia and other low-grade lymphomas.
- Outline current developments in the biology and pathogenesis of T cell and natural killer cell lymphomas.
- Develop opportunities for improved collaborations among investigators in the field.
Previous meetings have attracted more than 300 professional attendees from at least 20 countries outside of North America, including more than 65 trainees and junior researchers.
Who Should Attend?
- Laboratory-based investigators
- Translational investigators
- Junior faculty and trainees
- Life sciences and biopharmaceutical industry
- Regulatory scientists
- Practitioners and other health professionals interested in lymphoma science
Session Titles and Focus of Each Session
- Session #1: Germinal Center Biology
Focus: This session will focus on the normal germinal center (GC) reaction. It will provide a basis for understanding the pathogenesis of GC B cell-derived lymphomas and will update participants on the newest insight into how the physiological GC reaction functions.
- Session #2: Novel Genetic and Epigenetic Mechanisms in Lymphomagenesis
Focus: This session will highlight the latest insights into the genetic and epigenetic alterations in the pathogenesis of lymphomas.
- Session #3: Disrupted Signaling Pathways and Microenvironment in Lymphoma
Focus: This session will focus on describing the important role disrupted signaling pathways and microenvironmental interactions have in lymphoma biology. Note that unlike session 2 which will cover lymphoma biology from the epi-genetics perspective, this session will highlight a more biochemical, cell biological and immunological point of view on lymphoma biology.
- Session #4: Understanding Mechanisms of Sensitivity and Resistance to Novel Therapies in Lymphoma
Focus: This session will focus on what is currently known about the identification of patients sensitive to specific novel therapeutic approaches, as well as what has been learned about resistance mechanisms that impair the success of such therapies.
- Session #5: NK/T-cell Lymphomas
Focus: This session will describe current developments in the biology and pathogenesis of T cell and NK cell lymphomas.
- Session #6: Germinal Center-Derived Lymphomas
Focus: The session will provide the audience an up-to-date overview on the biology of the main subtypes of GC B cell-derived lymphomas. It will also cover lymphomas (e.g., Burkitt lymphoma, Hodgkin lymphoma and perhaps PMBCL) that will not be covered in sessions 2-4.
- Session #7: Chronic Lymphocytic Leukemia and other Small B cell Neoplasms
Focus: This session will focus on describing recent novel findings in CLL and other low-grade lymphomas that are not covered in other sessions.
- Session #8: Immunotherapies of Lymphomas
Focus: This session will describe the current development of immunotherapies for lymphomas.
- Session #9: Late Breaking Topics
This session will be developed later in the year based on emerging science in the field.
Steering Committee Members
- Laura Pasqualucci, MD, Columbia University [Co-chair]
- Elias Campo, MD, PhD, University of Barcelona [Co-chair]
- Ralf Küppers, PhD, University of Duisburg-Essen [Co-chair]
- Catherine Bollard, MD, MbChB, Children’s National Medical Center
- Wing C. (John) Chan, MD, City of Hope Medical Center
- Dan Landau, MD, PhD, New York City Genome Center
- Ronald Levy, MD, Stanford University
- Bertrand Nadel, PhD, French National Institute of Health and Medical Research
- Margaret Shipp, MD, Dana Farber Cancer Institute
- Louis Staudt, MD, PhD, National Cancer Institute
- Christian Steidl, MD, British Columbia Cancer Agency
- Karin Tarte, PharmD, PhD, University of Rennes
- Margot Thome-Miazza, PhD, University of Lausanne
Please submit all general inquiries to email@example.com. For information about sponsoring and/or exhibiting at MLB, contact SPARGO, Inc. at 800-564-4220, 703-631-6200, or firstname.lastname@example.org.
back to top